Biotechnology
Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights
SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2023 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2023, Alphamab Onc...
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative position compared to the corresponding period of las...
Broncus Medical (02216.HK) Announces Annual Results for 2023
The treatment products R&D continue to lead, and product sales are steadily advancing. HANGZHOU, China, March 28, 2024 /PRNewswire/ -- On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US...
Sirnaomics Announces 2023 Annual Results
Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products STP705, STP707 and STP122G HONG KONG, Germantown, Md. and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; st...
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...
ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis
LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release
of the report "A White Paper To Understand The Market Structure Of Pediatric
Pertussis Hexavalent and Combination Vaccines
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...
Scivita Medical Expands Collaboration with Boston Scientific
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical
Technology Co., Ltd. ("Scivita Medical") and Boston
Scientific Corporation (NYSE: BSX), a leading global medical technology
company, joined hands again to sign an expanded strategic cooperation
arrangement.
BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167
SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...
Medipledge, a premium post-laser skincare brand, just launched in Australia
SYDNEY, March 25, 2024 /PRNewswire/ -- On March 24th, 2024, Medipledge, a premium skincare brand developed by experts in beauty and dermatology, successfully launched inAustralia. The launch event, held in Australia, featured high-tech elements and included high-end aesthetic therapists, lead...
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
SINGAPORE, March 25, 2024 /PRNewswire/ -- Juniper Biologics
Veeva Vault EDC Surpasses 1,000 Study Start Milestone
Eight of the top 20 biopharmas standardize on Vault EDC to build a modern
clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...
NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused onin vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents si...
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
Week's Top Stories
Most Reposted
iKala Secures Over $20 Million in Series B+ Funding, Led by Chunghwa Telecom
[Picked up by 280 media titles]
2024-03-26 16:45Strengthening Interconnected Tourism Exchanges along the "21st Century Maritime Silk Road" Sanya Embarks on Tourism Marketing and Promotion Activities in Singapore
[Picked up by 276 media titles]
2024-03-22 21:46Chronicling ASEAN-China Friendship and Cooperation
[Picked up by 270 media titles]
2024-03-26 15:00Giti Tire Embarks on a Greener Future with New Chief Sustainability Officer
[Picked up by 263 media titles]
2024-03-25 09:00To jointly build equal, orderly multipolar world
[Picked up by 247 media titles]
2024-03-28 14:27